Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DESI drug compliance policy guide

This article was originally published in The Tan Sheet

Executive Summary

FDA announces draft compliance policy guide Oct. 17 for drugs that were subject to the Drug Efficacy Study Implementation program and are marketed without an approved NDA or ANDA. Guide outlines FDA policies to encourage companies to sponsor drugs through the approval process. Document also describes for public comment the agency's enforcement approach, which gives highest priority to products that pose the most likely risk to public safety, either because of inherent safety concerns or because there are alternative, FDA-approved treatments available, the agency said. Development of guide was prompted by petition from a group of manufacturers and distributors of Rx extended-release guaifenesin, which have been directed by FDA to remove their products from the market because they have not cleared the approval process (1"The Tan Sheet" March 3, 2003, p. 4)...

You may also be interested in...

Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says

Single-ingredient, extended-release prescription guaifenesin products must be removed from the market by the end of November if they have not been approved by FDA, the agency states in Feb. 25 letters to 66 marketers and distributors of the drugs

AAM Urges Trump Not To Destabilize Supply Chain

The AAM has warned the Trump administration that ‘Buy American’ requirements on medicines could limit patient access to affordable medicines and increase the risk of drug shortages during the coronavirus pandemic.

FDA Moves MDUFA V Meeting To May

The US agency has pushed to next month a public meeting on the latest incarnation of the Medical Device User Fee Amendments. The meeting will be held remotely.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts